Edaravone Dexborneol Versus Edaravone Alone for the Treatment of Acute Ischemic Stroke: A Phase III, Randomized, Double-Blind, Comparative Trial

依达拉奉 医学 改良兰金量表 随机化 麻醉 内科学 随机对照试验 临床试验 缺血性中风 缺血
作者
Jie Xu,Anxin Wang,Xia Meng,Gulbahram Yalkun,Anding Xu,Zhiqiang Gao,Dawei Chen,Yong Ji,Jun Xu,Deqin Geng,Runxiu Zhu,Bo Liu,Aiqin Dong,Hua Mu,Zhihong Lu,Shuya Li,Huaguang Zheng,Xia Chen,Yilong Wang,Xingquan Zhao
出处
期刊:Stroke [Lippincott Williams & Wilkins]
卷期号:52 (3): 772-780 被引量:288
标识
DOI:10.1161/strokeaha.120.031197
摘要

Background and Purpose: Edaravone dexborneol, comprised of 2 active ingredients, edaravone and (+)-borneol, has been developed as a novel neuroprotective agent with synergistic effects of antioxidant and anti-inflammatory in animal models. The present clinical trial aimed at testing the effects of edaravone dexborneol versus edaravone on 90-day functional outcome in patients with acute ischemic stroke (AIS). Methods: A multicenter, randomized, double-blind, comparative, phase III clinical trial was conducted at 48 hospitals in China between May 2015 and December 2016. Inclusion criteria included patients diagnosed as AIS, 35 to 80 years of age, National Institutes of Health Stroke Scale Score between 4 and 24, and within 48 hours of AIS onset. AIS patients were randomized in 1:1 ratio into 2 treatment arms: 14-day infusion of edaravone dexborneol or edaravone injection. The primary end point was the proportion of patients with modified Rankin Scale score ≤1 on day 90 after randomization. Results: One thousand one hundred sixty-five AIS patients were randomly allocated to the edaravone dexborneol group (n=585) or the edaravone group (n=580). The edaravone dexborneol group showed significantly higher proportion of patients experiencing good functional outcomes on day 90 after randomization, compared with the edaravone group (modified Rankin Scale score ≤1, 67.18% versus 58.97%; odds ratio, 1.42 [95% CI, 1.12–1.81]; P =0.004). The prespecified subgroup analyses indicated that a greater benefit was observed in female patients than their male counterparts (2.26, 1.49–3.43 versus 1.14, 0.85–1.52). Conclusions: When edaravone dexborneol versus edaravone was administered within 48 hours after AIS, 90-day good functional outcomes favored the edaravone dexborneol group, especially in female patients. Registration: URL: https://www.clinicaltrials.gov . Unique identifier: NCT02430350.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
zcc发布了新的文献求助10
刚刚
3秒前
小孟完成签到,获得积分10
3秒前
烹鱼宴糊锅完成签到,获得积分10
4秒前
4秒前
勤恳的皮皮虾完成签到,获得积分10
4秒前
4秒前
共享精神的应助被KobeLaoda采纳,获得10
5秒前
风清月莹完成签到,获得积分10
5秒前
5秒前
著名发布了新的文献求助10
6秒前
司徒宝完成签到,获得积分10
6秒前
天天玩完成签到,获得积分10
6秒前
CIci发布了新的文献求助10
6秒前
李爱国的应助被QianShenYu采纳,获得10
7秒前
粗犷的薯片关注了科研通微信公众号
9秒前
伯赏夏彤完成签到,获得积分10
9秒前
9秒前
梨色完成签到,获得积分10
10秒前
万能图书馆的应助被六六采纳,获得10
10秒前
10秒前
泽锦臻完成签到,获得积分10
11秒前
Marina完成签到 ,获得积分10
11秒前
CIci完成签到,获得积分10
12秒前
苦瓜大王发布了新的文献求助10
12秒前
天天快乐的应助被MM采纳,获得10
13秒前
panjunlu完成签到,获得积分10
13秒前
13秒前
14秒前
15秒前
15秒前
活泼万天完成签到,获得积分10
15秒前
小秦大qq发布了新的文献求助10
16秒前
SY完成签到,获得积分10
17秒前
17秒前
QianShenYu完成签到,获得积分10
17秒前
17秒前
17秒前
18秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8168423
求助须知:如何正确求助?哪些是违规求助? 9561356
关于积分的说明 21761245
捐赠科研通 7759810
什么是DOI,文献DOI怎么找? 3429998
关于科研通互助平台的介绍 2553872
邀请新用户注册赠送积分活动 2474665